Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study (Phase II) of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

NCT04243109 is registered in ClinicalTrials.gov with Maimónides Biomedical Research Institute of Córdoba as lead sponsor.

NCT NCT04243109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04243109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study (Phase II) of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Phase
Phase 2
Overall status
Terminated
Start date
February 23, 2017
Completion date
May 7, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma